Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Citizens JMP raised its price target on Acadia Pharmaceuticals (NASDAQ:ACAD) to $38.00 from $37.00 on Thursday, while maintaining a Market Outperform rating on the stock. The biopharmaceutical company, currently valued at nearly $4 billion, has demonstrated strong financial health with a robust balance sheet showing more cash than debt, according to InvestingPro data.
The price target increase follows Acadia’s second-quarter 2025 financial results, which exceeded both Citizens JMP’s and consensus estimates. The company reported in-line sales for its NUPLAZID product, while its DAYBUE medication drove the overall revenue beat. This performance aligns with the company’s impressive 22.4% revenue growth over the last twelve months.
In response to continued strength in NUPLAZID sales, Acadia management has raised the lower end of its revenue guidance range for the year, according to Citizens JMP.
The research firm noted that key pipeline catalysts for Acadia remain on track, with near-term focus on Phase 3 results for ACP-101 in Prader-Willi Syndrome, expected in early fourth quarter of 2025.
Citizens JMP described Acadia’s commercial performance as reflecting "success of strategic optimizations and investments," supporting its continued Market Outperform rating on the stock.
In other recent news, ACADIA Pharmaceuticals Inc. reported its Q2 2025 earnings, exceeding Wall Street forecasts. The company achieved an earnings per share (EPS) of $0.16, surpassing the predicted $0.14, which constitutes a 14.29% surprise. Revenue for the quarter was $264.6 million, slightly above the expected $262.44 million. These results mark a positive development for ACADIA Pharmaceuticals. The earnings and revenue figures are crucial indicators for investors, reflecting the company’s performance. Additionally, the stock showed a positive reaction in aftermarket trading, although specific price movements are not the focus here. These recent developments highlight ACADIA Pharmaceuticals’ financial health and operational success.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.